CLPT
ClearPoint Neuro, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$10.09
+3.96%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 45.5M | 37.0M | 31.4M | 24.0M | 20.6M |
| Cost of Revenue | 17.6M | 14.3M | 12.3M | 10.3M | 7.0M |
| Gross Profit | 27.9M | 22.7M | 19.1M | 13.6M | 13.5M |
| Operating Expenses | |||||
| R&D Expense | 16.4M | 13.9M | 12.4M | 11.7M | 10.9M |
| SG&A Expense | 44.0M | 33.0M | 26.5M | 24.4M | 19.0M |
| General & Admin Expense | 20.2M | 16.5M | 12.0M | 11.8M | 9.6M |
| Selling & Marketing Expense | 23.8M | 16.5M | 14.5M | 12.6M | 9.4M |
| Other Expenses | (400.0K) | — | — | — | — |
| Total Operating Expenses | 60.0M | 46.9M | 38.9M | 36.1M | 29.9M |
| Cost and Expenses | 77.6M | 61.1M | 51.1M | 46.4M | 36.9M |
| Operating Income (EBIT) | (32.1M) | (24.2M) | (19.7M) | (22.4M) | (16.3M) |
| Non-Operating | |||||
| Interest Income | 932.0K | 1.2M | 872.0K | 386.0K | — |
| Interest Expense | 4.9M | 2.4M | — | — | 81.0K |
| Net Interest Income | (4.0M) | (1.2M) | 872.0K | 386.0K | (81.0K) |
| Other Non-Op Income/Expense | (4.1M) | (1.3M) | 832.0K | 357.0K | (103.0K) |
| Non-Operating Income (excl Interest) | (282.0K) | (1.1M) | (832.0K) | (357.0K) | 22.0K |
| EBT (Pre-Tax Income) | (36.2M) | (25.5M) | (18.9M) | (22.1M) | (16.4M) |
| Income Tax Expense | (30.0K) | 55.0K | — | — | — |
| Bottom Line | |||||
| Net Income | (36.1M) | (25.5M) | (18.9M) | (22.1M) | (16.4M) |
| Earnings from Cont. Ops | (36.1M) | (25.5M) | (18.9M) | (22.1M) | (16.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (36.1M) | (25.5M) | (18.9M) | (22.1M) | (16.4M) |
| Per Share | |||||
| Basic EPS | ($1.21) | ($0.90) | ($0.70) | ($0.90) | ($0.68) |
| Diluted EPS | ($1.21) | ($0.90) | ($0.70) | ($0.90) | ($0.68) |
| Revenue Per Share | $1.47 | $1.31 | $1.16 | $0.97 | $0.85 |
| Shares | |||||
| Basic Shares Outstanding | 31.0M | 28.3M | 27.0M | 24.6M | 24.2M |
| Diluted Shares Outstanding | 31.0M | 28.3M | 27.0M | 24.6M | 24.2M |
| Profitability Metrics | |||||
| EBITDA | (26.9M) | (20.9M) | (17.0M) | (20.6M) | (15.6M) |
| D&A | 5.0M | 2.2M | 1.9M | 1.5M | 777.0K |
| EBIT | (31.8M) | (23.1M) | (18.9M) | (22.1M) | (16.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026